The writing was on the wall for InDex after cobitolimod flopped for ulcerative colitis but that should soon been scrubbed off now a reverse-merger candidate has been identified to save the Stockholm-based biotech from liquidation.

The Swedish biotech's hopes of advancing cobitolimod lie in tatters after a Phase III study of the TLR9 agonist proved futile.

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.